Toboroz
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637· 3. fázis· AstraZeneca· Forrás
Toboroz
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666· 3. fázis· AstraZeneca· Forrás
Toboroz
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978· 3. fázis· AstraZeneca· Forrás
Toboroz
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597· 4. fázis· AstraZeneca· Forrás
Toboroz
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658· 2. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702· 2. fázis· AstraZeneca· Forrás
Toboroz
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· 3. fázis· AstraZeneca· Forrás
Toboroz
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782· 1/2. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161· 1/2. fázis· AstraZeneca· Forrás
Toboroz
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646· 1/2. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Contact: Alexion Pharmaceuticals, Inc. (Sponsor)
Toboroz
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457· 1/2. fázis· AstraZeneca· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024· 2. fázis· AstraZeneca· Forrás
Toboroz
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665· 3. fázis· AstraZeneca· Forrás
Toboroz
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099· 2. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864· 3. fázis· AstraZeneca· Forrás
Contact: AstraZeneca Breast Cancer Study Locator Service
Fut, nem toboroz
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171· 1. fázis· Arcus Biosciences, Inc.· Forrás
Toboroz
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861· 3. fázis· DalCor Pharmaceuticals· Forrás
Contact: David Kallend, MBBS
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589· 3. fázis· AstraZeneca· Forrás
Toboroz
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644· 3. fázis· AstraZeneca· Forrás
Toboroz
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168· 1/2. fázis· AstraZeneca· Forrás
Toboroz
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Toboroz
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141· 1. fázis· Arcus Biosciences, Inc.· Forrás
Contact: Medical Director
Fut, nem toboroz
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
NCT04512235· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
NCT04504825· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957· 3. fázis· AstraZeneca· Forrás
Showing 50 of 57.